5-fluorouracil induced intestinal mucositis via nuclear factor-κB activation by transcriptomic analysis and in vivo bioluminescence imaging

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Chang, Chung Ta ^a,b   Ho, Tin Yun ^c   Lin, Ho ^b   Liang, Ji An ^d   Huang, Hui Chi ^c   Li, Chia Cheng ^c   Lo, Hsin Yi ^c   Wu, Shih Lu ^c   Huang, Yi Fang ^e   Hsiang, Chien Yun ^c  

^a FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL CHUNG HSING UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MESALAZINE; MYELOPEROXIDASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC ANTIMETABOLITE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIGESTIVE SYSTEM INFLAMMATION; DRUG INDUCED DISEASE; DRUG TARGETING; ENZYME ACTIVATION; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTESTINE CRYPT; INTESTINE MUCOSA; INTESTINE VILLUS; INTESTINE WALL; MALE; MOUSE; MUCOSA INFLAMMATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; TRANSCRIPTOMICS; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; GENETICS; METABOLISM; MOLECULAR IMAGING; PATHOLOGY; SMALL INTESTINE; TRANSGENIC MOUSE;

MUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMETABOLITES, ANTINEOPLASTIC; ENZYME ACTIVATION; FLUOROURACIL; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; INTESTINAL MUCOSA; INTESTINE, SMALL; MALE; MESALAMINE; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MOLECULAR IMAGING; MUCOSITIS; NF-KAPPA B; TRANSCRIPTIONAL ACTIVATION;

EID: 84863230356     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0031808     Document Type: Article

References (40)

1. Sausville EA, Longo DL, (2001) Principles of cancer treatment. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, editors. Harrison's Principles of Internal Medicine pp. 530-546 The McGraw-Hill Companies: New York.
2. Longley DB, Harkin DP, Johnston PG, (2003) 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338.
3. Gradishar WJ, Vokes EE, (1990) 5-Fluorouracil cardiotoxicity: a critical review. Ann Oncol 1: 409-414.
4. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, et al. (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100: 1995-2025.
5. Naidu MU, Ramana GV, Rani PU, Mohan IK, Suman A, et al. (2004) Chemotherapy-induced and/or radiation therapy-induced oral mucositis-complicating the treatment of cancer. Neoplasia 6: 423-431.
6. Sonis ST, (2004) The pathobiology of mucositis. Nat Rev Cancer 4: 277-284.
7. Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, et al. (2009) Is the pathobiology of chemotherapy-induced alimentary tract mucositis influenced by the type of mucotoxic drug administered? Cancer Chemother Pharmacol 63: 239-251.
8. Pritchard DM, Jackman A, Potten CS, Hickman JA, (1998) Chemically-induced apoptosis: p21 and p53 as determinants of enterotoxin activity. Toxicol Lett 102-103: 19-27.
9. Sonis ST, O'Donnell KE, Popat R, Bragdon C, Phelan S, et al. (2004) The relationship between mucosal cyclooxygenase-2 (COX-2) expression and experimental radiation-induced mucositis. Oral Oncol 40: 170-176.
10. Leitão RF, Ribeiro RA, Bellaguarda EA, Macedo FD, Silva LR, et al. (2007) Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster. Cancer Chemother Pharmacol 59: 603-612.
11. Logan RM, Stringer AM, Bowen JM, Yeoh AS, Gibson RJ, et al. (2007) The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 33: 448-460.
12. Soares PM, Lima-Junior RC, Mota JM, Justino PF, Brito GA, et al. (2011) Role of platelet-activating factor in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. Cancer Chemother Pharmacol in press.
13. Barnes PJ, Karin M, (1997) Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066-1071.
14. Bonizzi G, Karin M, (2004) The two NF-κB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25: 280-288.
15. Baldwin AS Jr, (1996) The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 14: 649-683.
16. Baeuerle PA, Baichwal VR, (1997) NF-κB as a frequent target for immunosuppressive and anti-inflammatory molecules. Adv Immunol 65: 111-137.
17. Ho TY, Chen YS, Hsiang CY, (2007) Noninvasive nuclear factor-κB bioluminescence imaging for the assessment of host-biomaterial interaction in transgenic mice. Biomaterials 28: 4370-4377.
18. Cheng HM, Li CC, Chen CYH, Lo HY, Cheng WY, et al. (2010) Application of bioactivity database of Chinese herbal medicine on the therapeutic prediction, drug development, and safety evaluation. J Ethnopharmacol 132: 429-437.
19. Hsiang CY, Chen YS, Ho TY, (2009) Nuclear factor-κB bioluminescence imaging-guided transcriptomic analysis for the assessment of hoist-biomaterial interaction in vivo. Biomaterials 30: 3042-3049.
20. Chang CT, Lin H, Ho TY, Li CC, Lo HY, et al. (2011) Comprehensive assessment of host responses to ionizing radiation by nuclear factor-κB bioluminescence imaging-guided transcriptomic analysis. PLoS ONE 6: e23682.
21. Smyth GK, (2005) Limma: linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and Computational Biology Solutions Using R and Bioconductor pp. 397-420 Springer: New York.
22. Bowen JM, Gibson RJ, Cummins AG, Keefe DM, (2006) Intestinal mucositis: the role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer 14: 713-731.
23. Bantel H, Berg C, Vieth M, Stolte M, Kruis W, et al. (2000) Mesalazine inhibits activation of transcription factor NF-κB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 95: 3452-3457.
24. Treister N, Sonis S, (2007) Mucositis: biology and management. Curr Opin Otolaryngol Head Neck Surg 15: 123-129.
25. Melo ML, Brito GA, Soares RC, Carvalho SB, Silva JV, et al. (2008) Role of cytokines (TNF-α, IL-1β and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemother Pharmacol 61: 775-784.
26. Wu Z, Han X, Qin S, Zheng Q, Wang Z, et al. (2010) Interleukin 1 receptor antagonist reduces lethality and intestinal toxicity of 5-fluorouracil in a mouse mucositis model. Biomed Pharmacother 64: 589-593.
27. Wu ZQ, Han XD, Wang Y, Yuan KL, Jin ZM, et al. (2011) Interleukin-1 receptor antagonist reduced apoptosis and attenuated intestinal mucositis in a 5-fluorouracil chemotherapy model in mice. Cancer Chemother Pharmacol in press.
28. Williams PD, Cheon S, Havaleshko DM, Jeong H, Cheng F, et al. (2009) Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Res 69: 8302-8309.
29. Motoori M, Takemasa I, Yamasaki M, Komori T, Takeno A, et al. (2010) Prediction of the response to chemotherapy in advanced esophageal cancer by gene expression profiling of biopsy samples. Int J Oncol 37: 1113-1120.
30. Schauer M, Janssen KP, Rimkus C, Raggi M, Feith M, et al. (2010) Microarray-based response prediction in esophageal adenocarcinoma. Clin Cancer Res 16: 330-337.
31. Petty RD, Samuel LM, Murray GI, MacDonald G, O'Kelly T, et al. (2009) APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinomas identified by gene expression profiling. BMC Cancer 9: 434.
32. Tsao DA, Chang HJ, Lin CY, Hsiung SK, Huang SE, et al. (2010) Gene expression profiles for predicting the efficacy of the anticancer drug 5-fluorouracil in breast cancer. DNA Cell Biol 29: 285-293.
33. Wu JT, Kral JG, (2005) The NF-κB/IκB signaling system: a molecular target in breast cancer therapy. J Surg Res 123: 158-169.
34. Campbell IK, Gerondakis S, O'Donnell K, Wicks IP, (2000) Distinct roles for the NF-κB1 (p50) and c-Rel transcription factors in inflammatory arthritis. J Clin Invest 105: 1799-1806.
35. Tomita N, Morishita R, Lan HY, Yamamoto K, Hashizume M, et al. (2000) In vivo administration of nuclear transcription factor-κB decoy suppresses experimental crescentic glomerulonephritis. J Am Soc Nephrol 11: 1244-1252.
36. Wu SL, Chen JC, Li CC, Lo HY, Ho TY, et al. (2009) Vanillin improves and prevents trinitrobenzene sulfonic acid-induced colitis in mice. J Pharmacol Exp Ther 330: 370-376.
37. Sonis ST, (2002) The biologic role for nuclear factor-κB in disease and its potential involvement in mucosal injury associated with anti-neoplastic therapy. Crit Rev Oral Biol Med 13: 380-389.
38. Aota K, Azuma M, Yamashita T, Tamatani T, Motegi K, et al. (2000) 5-Fluorouracil induces apoptosis through the suppression of NF-κB activity in human salivary gland cancer cells. Biochem Biophys Res Commun 273: 1168-1174.
39. Azuma M, Yamashita T, Aota K, Tamatani T, Sato M, (2001) 5-Fluorouracil suppression of NF-κB is mediated by the inhibition of IκB kinase activity in human salivary gland cancer cells. Biochem Biophys Res Commun 282: 292-296.
40. Kaltschmidt B, Kaltschmidt C, Hofmann TG, Hehner SP, Droge W, et al. (2000) The pro- or anti-apoptotic function of NFκB is determined by the nature of the apoptotic stimulus. Eur J Biochem 267: 3828-3835.